TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06350149

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugar Sweetened Beverages (SSB)
Description: The following are considered SSBs: non-diet soft drinks/sodas, flavored juice drinks, sweetened tea, energy drinks, and electrolyte replacement drinks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugar Sweetened Beverages (SSB)
Description: The following are considered SSBs: non-diet soft drinks/sodas, flavored juice drinks, sweetened tea, energy drinks, and electrolyte replacement drinks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hi GI
Description: The Glycemic Index of the high-GI meals will be at least 75

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hi GI
Description: The Glycemic Index of the high-GI meals will be at least 75

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lo GI
Description: The Glycemic Index of the low- -GI meals will not be higher than 55.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lo GI
Description: The Glycemic Index of the low- -GI meals will not be higher than 55.
Study: NCT06398444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium[177Lu] Oxodotreotide Injection
Description: Participants will receive 7.4GBq (200mCi) Lutetium\[177Lu\] Oxodotreotide Injection every 8 weeks.
Study: NCT05371834

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microwave Treatment (Swift System)
Description: Localized microwave energy applied to the wart lesion. Treatment is in 4-week intervals (minimum of 2 treatments, maximum of 4 treatments).~For common warts (usually hands, elbow, knees): Treatment starts at 6W and applied locally for a 2 second burst and the dose and duration is adjusted (up or down) as is tolerable for the subject. Treatment is repeated on the same wart as is tolerable (3-5 repetitions).~For plantar warts: Treatment starts at 8W and applied locally for a 2 second burst and the dose and duration is adjusted (up or down) as is tolerable for the subject. Treatment is repeat on the same wart as is tolerable (3-5 repetitions).~Less power for a longer time will result in a more gradual temperature rise. Higher power for a shorter time will result in a more immediate temperature rise.
Study: NCT06211127

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold laser plaque ablation
Description: Patients were randomly divided into two groups. After being included in the two groups, different laser equipment was used to revascularize the lower limbs. The patients' revascularization status was evaluated through regular follow-up after surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The excimer laser
Description: Patients were randomly divided into two groups. After being included in the two groups, different laser equipment was used to revascularize the lower limbs. The patients' revascularization status was evaluated through regular follow-up after surgery.
Study: NCT05371834

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: Local application of Cryotherapy. Treatment is in 4-week intervals (minimum of 2 treatments, maximum of 4 treatments).
Study: NCT05945069

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TriLift device
Description: Dynamic Muscle Stimulation combined with tripolar Radiofrequency, administered on the skin of the inferior orbital rim and below the lower eyelids
Study: NCT05655533

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance Imaging scanners of sacroiliac joints.
Description: Patients will undergo MR imaging examinations with a closed 1.5-Tesla Magnetic resonance Imaging scanners of sacroiliac joints.~The patients will be imaged in the supine position using a body phased-array coil.~Evaluate the added value of DWI in detection of acute sacroiliitis and whether ADC values can be helpful in detection and differentiation of active stage, so determine whether supplementation of DWI with quantitative ADC mapping to the routine MR examination is of great value as non-invasive tool or not
Study: NCT06035406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retagliptin Phosphate Tablet
Description: Retagliptin Phosphate Tablet;100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retagliptin Phosphate Tablet
Description: Retagliptin Phosphate Tablet;100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retagliptin Phosphate Tablet
Description: Retagliptin Phosphate Tablet;100mg
Study: NCT04321954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LENVATINIB
Description: Orally
Study: NCT05390307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide / Semaglutide
Description: Liraglutide 3mg once daily or semaglutide 1mg once weekly subcutaneous injection for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin 5-10 mg once daily for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide or Semaglutide / Dapagliflozin
Description: Combined treatment with Liraglutide 3mg once daily or semaglutide 1mg once weekly subcutaneous injection plus Dapagliflozin 5-10 mg once daily for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide or Semaglutide / Dapagliflozin plus intensive weight loss nutrition
Description: Liraglutide 3mg once daily or semaglutide 1mg once weekly subcutaneous injection plus Dapagliflozin 5-10 mg once daily for 6 months combined with intensive lifestyle changes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual standard care
Study: NCT05934955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1839100
Description: BI 1839100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1839100
Description: BI 1839100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1839100
Description: BI 1839100

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BI 1839100
Description: Placebo matching BI 1839100
Study: NCT05199519

Intervention type: DRUG
Group type: OTHER
Intervention: IBI345
Description: IBI345 CAR-T cell injection by intravenous infusion
Study: NCT05151510

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trigger point injection with 1% lidocaine
Description: Previously discussed in prior section.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine patch 5%
Description: Will place lidocaine patch onto skin overlaying point of maximal tenderness
Study: NCT06526182

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Lebrikizumab solution for injection administered subcutaneously.
Study: NCT05059301

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA investigational vaccine
Description: One dose of a unique combination of the RSVPreF3 antigen lots (Lot 1, Lot 2 or Lot 3) and extemporaneously reconstituted with AS01E adjuvant lots (Lot A, Lot B and Lot C), administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA investigational vaccine
Description: One dose of a unique combination of the RSVPreF3 antigen lots (Lot 1, Lot 2 or Lot 3) and extemporaneously reconstituted with AS01E adjuvant lots (Lot A, Lot B and Lot C), administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA investigational vaccine
Description: One dose of a unique combination of the RSVPreF3 antigen lots (Lot 1, Lot 2 or Lot 3) and extemporaneously reconstituted with AS01E adjuvant lots (Lot A, Lot B and Lot C), administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1.
Study: NCT05319808

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: Individualized treatment of manual therapy provided by MT PTs, graduates from Curtin University of Technology, Perth, Australia (2008)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: Individualized treatment of manual therapy provided by MT PTs, graduates from Curtin University of Technology, Perth, Australia (2008)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telehealth exercises
Description: A novel, remote computer based cervical joint positioning exercise and cervical kinaesthetic exercise (CKE) program. A technical consultant monitors the data from the remote exercises and inform the PTs if someone has not done their exercises in over 2 weeks during the study period so subjects can be encouraged with a friendly reminder.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-computer based exercises
Description: Home-exercises in the need of each subject (pragmatic approach) taught by MT PTs, graduates from Curtin University of Technology, Perth, Australia (2008)
Study: NCT05815095

Intervention type: OTHER
Intervention: PREAUT grid
Description: Patient with abnormal results in this evaluation would be referred to a specialized center early for advice and treatment if necessary
Study: NCT05142696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-DOTA-TATE
Description: Solution for infusion of \[177Lu\]Lu-DOTA-TATE will be administered as follows:~* 2 administrations during the induction period on either Day 3, 4 or 5 of Week 1 and on Week 7 Day 3~* 1 to 4 administrations during the maintenance period on Week 13 Day 1, Week 16 Day 1, Week 19 Day 1 and Week 22 Day 1, depending on the dose assessed
Study: NCT06047483

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo ，external use，once a day
Study: NCT06344663

Intervention type: OTHER
Intervention: motivational interview
Description: Before starting the interview, mothers will be informed about the interview intervals, duration, how many times it will be held, and that, unlike other interviews, the topic will be determined and the mother's opinions on this subject will be obtained. Each meeting will last approximately 15-30 minutes
Study: NCT05142696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-DOTA-TATE
Description: Solution for infusion of \[177Lu\]Lu-DOTA-TATE will be administered as follows:~* 2 administrations during the induction period on either Day 3, 4 or 5 of Week 1 and on Week 7 Day 3~* 1 to 4 administrations during the maintenance period on Week 13 Day 1, Week 16 Day 1, Week 19 Day 1 and Week 22 Day 1, depending on the dose assessed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-DOTA-TATE
Description: Solution for infusion of \[177Lu\]Lu-DOTA-TATE will be administered as follows:~* 2 administrations during the induction period on either Day 3, 4 or 5 of Week 1 and on Week 7 Day 3~* 1 to 4 administrations during the maintenance period on Week 13 Day 1, Week 16 Day 1, Week 19 Day 1 and Week 22 Day 1, depending on the dose assessed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-DOTA-TATE
Description: Solution for infusion of \[177Lu\]Lu-DOTA-TATE will be administered as follows:~* 2 administrations during the induction period on either Day 3, 4 or 5 of Week 1 and on Week 7 Day 3~* 1 to 4 administrations during the maintenance period on Week 13 Day 1, Week 16 Day 1, Week 19 Day 1 and Week 22 Day 1, depending on the dose assessed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-DOTA-TATE
Description: Solution for infusion of \[177Lu\]Lu-DOTA-TATE will be administered as follows:~* 2 administrations during the induction period on either Day 3, 4 or 5 of Week 1 and on Week 7 Day 3~* 1 to 4 administrations during the maintenance period on Week 13 Day 1, Week 16 Day 1, Week 19 Day 1 and Week 22 Day 1, depending on the dose assessed
Study: NCT06444971

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post isometric Relaxation
Description: Post isometric relaxation technique: It is defined as a manual procedure which involves the precisely controlled and specifically directed active contraction of a muscle at varying levels of intensity against a counterforce applied by the therapist.~PIR will be applied to following muscles~1. scalene (anterior, middle and posterior)~2. sternocleidomastoid
Study: NCT06557460

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical implantation of the CPCB-RPE1 implant
Description: Surgical implantation of the CPCB-RPE1 implant

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Surgical implantation of the CPCB-RPE1 implant
Description: Surgical implantation of the CPCB-RPE1 implant
Study: NCT05947396

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SMARTO ONE
Description: The SMARTO ONE® small molecule natural flavonoid compound product is provided by Beijing Jiafurui Biological Technology Co., Ltd. The intervention agent formula consists of extracts from Polygonum cuspidatum leaves, Fructus ligustri lucidi, Prunus mume, Semen ziziphi spinosae, celery, resistant maltodextrin, and steviol glycoside. Each package of the test product (3g) contains a total flavonoid content of 150mg.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo is provided by Beijing Jiafurui Biological Technology Co., Ltd. The formula consists of maltodextrin, grapefruit powder, and food coloring. The manufacturing facility has adjusted the appearance, color, solubility, and taste of the placebo to match the intervention agent. There is no risk of unblinding.
Study: NCT05111171

Intervention type: DEVICE
Intervention: sheath
Description: Senior interventional doctors interpret the CAG results and group according to their clinical experience: (1) No PCI is required, only diagnostic CAG is required, which is group ①6F sheath CAG group; (2) PCI is required, simple lesions are group ②6F sheath PCI group, the 6F sheath is still used for PCI; (3) PCI is required for the complicated disease and use 7F sheath, as the 7F sheath PCI group is the group ③, and the 7F sheath is replaced for PCI.

Intervention type: DEVICE
Intervention: sheath
Description: Senior interventional doctors interpret the CAG results and group according to their clinical experience: (1) No PCI is required, only diagnostic CAG is required, which is group ①6F sheath CAG group; (2) PCI is required, simple lesions are group ②6F sheath PCI group, the 6F sheath is still used for PCI; (3) PCI is required for the complicated disease and use 7F sheath, as the 7F sheath PCI group is the group ③, and the 7F sheath is replaced for PCI.

Intervention type: DEVICE
Intervention: sheath
Description: Senior interventional doctors interpret the CAG results and group according to their clinical experience: (1) No PCI is required, only diagnostic CAG is required, which is group ①6F sheath CAG group; (2) PCI is required, simple lesions are group ②6F sheath PCI group, the 6F sheath is still used for PCI; (3) PCI is required for the complicated disease and use 7F sheath, as the 7F sheath PCI group is the group ③, and the 7F sheath is replaced for PCI.
Study: NCT04336943

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06365372

Intervention type: DIAGNOSTIC_TEST
Intervention: Western blot
Description: Samples were measured by Western blot using a solution for the separation of lymphocytes from peripheral blood.

Intervention type: DIAGNOSTIC_TEST
Intervention: Western blot
Description: Samples were measured by Western blot using a solution for the separation of lymphocytes from peripheral blood.
Study: NCT06047106

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: multiparametric MRI
Description: For the living donor, multiparametric MRI will be added in the day hospital: at the pre-transplant assessment and at the 12-month post-transplant assessment.~For the recipient: multiparametric MRI will be added in the day hospital at the time of the systematic assessment at 1 month post-transplant, and will be added in the day hospital at the time of the 12-month post-transplant assessment.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: multiparametric MRI
Description: For the living donor, multiparametric MRI will be added in the day hospital: at the pre-transplant assessment and at the 12-month post-transplant assessment.~For the recipient: multiparametric MRI will be added in the day hospital at the time of the systematic assessment at 1 month post-transplant, and will be added in the day hospital at the time of the 12-month post-transplant assessment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: kidney graft biopsy
Description: Biopsy of the graft itself prior to transplantation in the recipient.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples
Description: For donors who are not selected to donate their kidney, a total of 2 mL of blood will be collected at inclusion.~For donors eligible to donate, a total of 4 mL of blood will be collected (at inclusion and at 12 months post-transplant).~For recipients, a total of 26 mL of blood will be collected (pre-transplant, 1 month and 12 months post-transplant).
Study: NCT05142696

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Four cycles of carboplatin AUC 5 on Day 1 every 3 weeks (Weeks 1, 4, 7 and 10) in induction period
Study: NCT05912361

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: receiving a one hour theoretical and hands on training session before using an AI-based platform
Description: The students at the experimental group will receive a one-hour hands-on training session before logging in to the online platform. The session will be presented by a dentist with AI experience and this session will present basic aspects of AI in radiology, deep learning (DL) applications for cariology and endodontics, as well as basics of excavation therapy and pulp exposure. the theoretical part will be followed by a hands on session on which each participant will check 11 cases of teeth with deep caries and will find the closest line between caries and pulp. their performance will be supervised by the training session presenter and the correct line will be shown them in case of making wrong line.
Study: NCT05142696

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Four cycles of etoposide 100 mg/m2 on Day 1-3, every 3 weeks (Weeks 1, 4, 7 and 10) in induction period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Four cycles of etoposide 100 mg/m2 on Day 1-3, every 3 weeks (Weeks 1, 4, 7 and 10) in induction period
Study: NCT06185335

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ANB-010, dose 1
Description: Adeno-associated viral vector carrying the FVIII gene single infusion at dose 1.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ANB-010, dose 2
Description: Adeno-associated viral vector carrying the FVIII gene single infusion at dose 2.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ANB-010, dose 3
Description: Adeno-associated viral vector carrying the FVIII gene single infusion at dose 3.
Study: NCT05142696

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Four cycles of etoposide 100 mg/m2 on Day 1-3, every 3 weeks (Weeks 1, 4, 7 and 10) in induction period
Study: NCT05608980

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.01% hypochlorous acid
Description: once daily 0.01% hypochlorous acid topical treatment via ultrasonic atomization for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily eyelid wipes for 2 weeks
Study: NCT05142696

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Four cycles of etoposide 100 mg/m2 on Day 1-3, every 3 weeks (Weeks 1, 4, 7 and 10) in induction period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Four cycles of etoposide 100 mg/m2 on Day 1-3, every 3 weeks (Weeks 1, 4, 7 and 10) in induction period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Four cycles of etoposide 100 mg/m2 on Day 1-3, every 3 weeks (Weeks 1, 4, 7 and 10) in induction period

Intervention type: OTHER
Group type: OTHER
Intervention: Etoposide
Description: Four cycles of etoposide 100 mg/m2 on Day 1-3, every 3 weeks (Weeks 1, 4, 7 and 10) in induction period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Four cycles of etoposide 100 mg/m2 on Day 1-3, every 3 weeks (Weeks 1, 4, 7 and 10) in induction period
Study: NCT06047106

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples
Description: For donors who are not selected to donate their kidney, a total of 2 mL of blood will be collected at inclusion.~For donors eligible to donate, a total of 4 mL of blood will be collected (at inclusion and at 12 months post-transplant).~For recipients, a total of 26 mL of blood will be collected (pre-transplant, 1 month and 12 months post-transplant).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: urine specimens
Description: For donors who are not selected to donate their kidney, a total of 15 mL of urine will be collected at inclusion.~For donors eligible to donate, a total of 50 mL of urine will be collected (at inclusion and at 12 months post-transplant).~For recipients, a total of 65 mL of urine will be collected (pre-transplant, 1 month and 12 months post-transplant).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: urine specimens
Description: For donors who are not selected to donate their kidney, a total of 15 mL of urine will be collected at inclusion.~For donors eligible to donate, a total of 50 mL of urine will be collected (at inclusion and at 12 months post-transplant).~For recipients, a total of 65 mL of urine will be collected (pre-transplant, 1 month and 12 months post-transplant).
Study: NCT05246475

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET-MRI
Description: Simultaneous PET-MRI measurement
Study: NCT06287242

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: spinal manipulation
Description: High velocity, low amplitude (HVLA) manipulation of the cervical or thoracic spine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: spinal manipulation
Description: High velocity, low amplitude (HVLA) manipulation of the cervical or thoracic spine
Study: NCT04896619

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kori tofu bread
Description: 34.5 grams of Kori-tofu, mixed in 3 slices of wheat bread.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein bread
Description: Matched whey protein, soy oil and maltodextrin/cellulose, mixed in 3 slices of wheat bread
Study: NCT06346431

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: DSPT - Digital Support for Problem-solving Therapy
Description: Mobile app breaking major treatment and social needs into subtasks, providing information, prompts and in-app payment to complete those tasks.